RESUMO
The importance of early diagnosis of hepatitis B virus infection to treat and follow up this disease has led to many advances in diagnostic techniques and materials. Conventional diagnostic tests are not very useful, especially in the early stages of infection; it is therefore suggested that nanomaterials can enhance them by changing and strengthening their performance for a more accurate and rapid diagnosis. Electrochemical immunosensors with unique features such as miniaturization, low cost, specificity, and simplicity have become a convenient and vital tool in the rapid diagnosis of hepatitis B. Different strategies have been presented, such as graphene oxide and gold nanorods [GO-GNRs], graphene oxide [GO], copper metal-organic framework/ electrochemically reduced graphene oxide [Cu-MOF/ErGO] composite, label-free graphene oxide/Fe3O4/Prussian Blue [GO/Fe3O4/PB] immunosensor, and graphene oxide-ferrocene-CS/Au [ GO-Fc-CS/Au] nanoparticle layered electrochemical immunosensor. In this review, we discuss a group of the most widely used nanostructures, such as graphene and carbon nanotubes, which are used to develop electrochemical immunosensors for the early diagnosis of the hepatitis B virus.
RESUMO
Background: Hepatitis A virus (HAV) can have severe manifestations in adult patients with other liver diseases, particularly in those infected with human immunodeficiency virus (HIV). This study aimed to measure immunity against HAV in HIV-positive individuals to determine the necessity of vaccination against HAV in this population. Methods: This cross-sectional study investigated 171 HIV-positive patients aged 18 years or older who were tested for serum IgG anti-viral hepatitis A antibody. The prevalence and its determinants were analyzed based on patient data. Results: The average age of the patients was 44.2 years old. The prevalence of HAV antibody positivity was 97.7%. The prevalence was higher in patients older than 30 years. There was a close association between hepatitis C virus (HCV) infection (P=0.002). There were no significant correlations between antibody levels and sex, marital status, employment status, education level, economic status, smoking status, drug use status, and physical activity level. The mean and median CD4+ counts in patients with positive (reactive) antibody (Ab) levels were 458 and 404±294, respectively, while the mean and median CD4+ counts in patients with non-reactive antibody levels were 806 and 737±137, respectively, in those who tested negative for anti-HAV Ab (P=0.05). Conclusion: The prevalence of anti-hepatitis A IgG antibodies in people with HIV was very high in Shiraz. There is an increasing trend in the number of older patients and those with HCV infections. The negative association with CD4 was borderline in this study, which needs to be confirmed in larger groups.
RESUMO
Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic small molecules to targeted cancer cells, leading to an enhanced therapeutic index through increased antitumor activity and decreased off-target toxicity. ADCs hold great promise for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after the approval and tremendous success of trastuzumab emtansine and trastuzumab deruxtecan, representing a turning point in both HER2-positive breast cancer treatment and ADC technology. Additionally and importantly, a total of 29 ADC candidates are now being investigated in different stages of clinical development for the treatment of HER2-positive breast cancer. The purpose of this review is to provide an insight into the ADC field in cancer treatment and present a comprehensive overview of ADCs approved or under clinical investigation for the treatment of HER2-positive breast cancer.
